Source: Defence Therapeutics.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Defence Therapeutics’ (DTC) AccuTOX compound has been shown to elicit cell death in cancer cells
  • The company discovered the compound’s novel cell DNA damaging function which may serve to treat numerous cancers
  • AccuTOX’s phase I trial in North America is forthcoming
  • Defence Therapeutics is a biotechnology company engineering the next generation of vaccines and antibody drug conjugates
  • Defence Therapeutics (DTC) is up by 15.56 per cent trading at $2.08 per share

Defence Therapeutics’ (DTC) AccuTOX compound has been shown to elicit cell death in cancer cells.

The mechanism of action involves a novel DNA damaging function triggered by the compound with potential applications across multiple cancers.

When combined with multiple immune-checkpoints, AccuTOX yields a survival rate between 60-100 per cent based on pre-clinical tumor model studies in mice.

Defence is conducting good laboratory practice (GLP) studies on AccuTOX prior to a phase I trial in North America.

“Defence’s breakthrough discovery with its AccuTOX formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with Accum,” stated Sébastien Plouffe, CEO of Defence Therapeutics.

“Discovering that AccuTOX can behave as a chemotherapeutic agent targeting the DNA of cancer cells and an immune-checkpoint inhibitor booster is a new discovery that is highly valuable to Defence’s pipeline and future potential developments,” he added.

Defence Therapeutics is a biotechnology company engineering the next generation of vaccines and antibody drug conjugates.

Defence Therapeutics (DTC) is up by 15.56 per cent trading at $2.08 per share as of 2:24 pm EST.


More From The Market Herald

" Marvel Biosciences Corp. (TSXV:MRVL) closes non-brokered private placement

Marvel Biosciences Corp. (MRVL)  has closed its previously announced non-brokered private placement for gross proceeds of $720,000.
Reliq Health Technologies - CEO Dr. Lisa Crossley

" Reliq Health Technologies (TSXV:RHT) announces eight new contracts

Reliq Health Technologies (RHT) has signed new contracts with six clinics and two physician practices in Idaho, New Mexico, California, Nevada and Texas.

" Is this company the next GW Pharma? Phase II study now underway

With the Covid pandemic now diminishing across most jurisdictions, now is a great time for investors to be looking at other pharma subsectors.

" Spectral Medical (TSX:EDT) subsidiary Dialco Medical and Marathon Medical awarded contract with the U.S. Department of Veterans Affairs

Spectral Medical (EDT) subsidiary Dialco Medical, and distribution partner Marathon Medical Corporation, have been awarded a five-year contract.